Bio-Rad Laboratories Inc. (BIO)
Bio-Rad's Q3 Earnings Miss Estimates, Revenues Surpass, Stock Falls
BIO's Q3 earnings fall short of estimates despite higher revenues, as margin pressure and weak research demand weigh on results.
Bio-Rad Laboratories, Inc. (BIO) Q3 2025 Earnings Call Transcript
Bio-Rad Laboratories, Inc. ( BIO ) Q3 2025 Earnings Call October 29, 2025 5:00 PM EDT Company Participants Yong Chung - Vice President of Investor Relations Jonathan DiVincenzo - President & COO Roop Lakkaraju - Executive VP & CFO Norman Schwartz - Chairman & CEO Conference Call Participants Patrick Donnelly - Citigroup Inc., Research Division Daniel Leonard - UBS Investment Bank, Research Division Brandon Couillard - Wells Fargo Securities, LLC, Research Division Tycho Peterson - Jefferies LLC, Research Division Jack Meehan - Nephron Research LLC Presentation Operator Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today.
Bio-Rad Laboratories (BIO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bio-Rad Laboratories, Inc. (BIO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 12:45 PM EDT Company Participants Roop Lakkaraju - Executive VP & CFO Norman Schwartz - Chairman & CEO Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Presentation Brandon Couillard MD & Equity Analyst Good afternoon. Welcome to the Wells Fargo Healthcare Conference.
Is it Apt to Hold Bio-Rad Stock in Your Portfolio Now?
BIO's strong ddPCR growth and solid diagnostics demand support its stock despite market pressures and stiff competition.
Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause
The U.S. Government plans to cut the annual budget allocated to the NIH by 40% in 2026. This decision could have an adverse effect on the operations of Bio-Rad. Bio-Rad projects 0.5% revenue growth for 2025, indicating that it encounters problems in expanding its operations. The four relative valuations conducted in this article reported mixed results. These results suggest that the company trades at fair value.
Bio-Rad Laboratories, Inc. (BIO) Q2 2025 Earnings Call Transcript
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q2 2025 Earnings Conference Call July 31, 2025 5:00 PM ET Company Participants Jonathan P. DiVincenzo - President & COO Norman D.
Earnings Preview: Bio-Rad Laboratories (BIO) Q2 Earnings Expected to Decline
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bio-Rad Stock Climbs Following the Launch of Four ddPCR Platforms
BIO surges 4% as the Stilla acquisition fuels the launch of four ddPCR systems, expanding to 400K+ assay offerings.
New Strong Sell Stocks for July 10th
BIO, DECK and ELUXY have been added to the Zacks Rank #5 (Strong Sell) List on July 10, 2025.
Investing in Bio-Rad (BIO)? Don't Miss Assessing Its International Revenue Trends
Explore Bio-Rad's (BIO) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
BIO Beats on Q1 Earnings, Lowers '25 View, Stock Up in Aftermarket
Bio-Rad witnesses first-quarter top-line decline in its Life Science segment, primarily due to challenges in the academic research market.
